Sona Nanotech Inc (TSE:SONA) has released an update.
Sona Nanotech Inc. is showcasing its Targeted Hyperthermia Therapy (THT) cancer treatment at the NCL’s 20th anniversary symposium, celebrating advances in cancer nanotechnology. The company has successfully completed initial safety studies for its gold nanorods, paving the way for further human trials in 2025.
For further insights into TSE:SONA stock, check out TipRanks’ Stock Analysis page.
